August has been a packed month for Huntington’s disease (HD) research. We’ve looked at what can be learned from disappointing ...
A new Phase 1 study is testing SRP-1005, a huntingtin-lowering therapy given by injection under the skin. It’s early days, ...
The expanded CAG repeat that causes HD sits within the very beginning of the huntingtin gene. Sometimes the huntingtin ...
Spark and Roche issued a joint community letter to share that the first patient has been dosed in a new HD gene therapy trial. To capture your interest with a romance, let’s talk about how these ...
In plain language. Written by scientists. A new Phase 1 study is testing SRP-1005, a huntingtin-lowering therapy given by injection under the skin. It’s early days, but this approach could add an ...
In plain language. Written by scientists. ⏱️7 min read | A recent study in pigs suggests the HD brain could be under attack from the body’s own immune system. The results reveal that invading ...
⏱️ 9 min read |New research in a HD mouse model points to a key culprit: a small fragment called HTT1a. Lowering HTT1a levels successfully delayed disease signs in mice that model HD, perhaps shaping ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results